...
首页> 外文期刊>Journal of the National Cancer Institute >Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study.
【24h】

Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study.

机译:系统性糖皮质激素使用者中的皮肤癌和非霍奇金淋巴瘤:一项基于人群的队列研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Patients treated with glucocorticoids may have an increased risk of skin cancer. Using data from the population-based North Jutland Prescription Database and the Danish Cancer Registry, we compared observed and expected numbers of cases of skin cancer and non-Hodgkin lymphoma among 59 043 individuals who received prescriptions for glucocorticoids, a common immunosuppressive therapy, during an 8-year period from January 1, 1989, through December 31, 1996. The overall risks for squamous cell carcinomas and basal cell carcinomas of the skin were increased, particularly among persons who had 15 or more prescriptions (standardized incidence ratio [SIR] for squamous cell carcinomas = 2.45, 95% confidence interval [CI] = 1.37 to 4.04; SIR for basal cell carcinomas = 1.52, 95% CI = 1.09 to 2.07). An elevated risk was also found for non-Hodgkin lymphoma among those with 10-14 prescriptions (SIR = 2.68, 95% CI = 1.16 to 5.29). Our data suggest that use of glucocorticoids may be a shared risk factor for certain skin cancers and lymphomas.
机译:用糖皮质激素治疗的患者患皮肤癌的风险可能增加。使用基于人群的北日德兰半岛处方数据库和丹麦癌症登记处的数据,我们比较了在接受治疗的59,043名接受糖皮质激素处方(一种常见的免疫抑制疗法)的人中,皮肤癌和非霍奇金淋巴瘤的病例数和预期数。从1989年1月1日到1996年12月31日的8年期间。皮肤鳞状细胞癌和基底细胞癌的总体风险增加了,特别是对于那些拥有15张或更多处方的患者(标准发生率[SIR])鳞状细胞癌= 2.45,95%置信区间[CI] = 1.37至4.04;基底细胞癌的SIR = 1.52,95%CI = 1.09至2.07)。服用10-14张处方的患者中非霍奇金淋巴瘤的风险也有所升高(SIR = 2.68,95%CI = 1.16至5.29)。我们的数据表明,使用糖皮质激素可能是某些皮肤癌和淋巴瘤的共同危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号